Obesity & GLP-1
GLP-1 incretins have become the largest drug class in pharma history, and the next phase of value shifts toward oral formulations, amylin-based next-gen mechanisms, and the manufacturing chain that supplies them.
The story
Obesity and type-2 diabetes treatment has consolidated into a duopoly of incretin platforms whose combined revenue already approaches the size of entire mid-cap drug categories, yet penetration of the addressable obese and overweight population remains low. The thesis hinges on adherence, payer coverage, and the transition from weekly injections to convenient oral and longer-interval dosing, which could widen the eligible patient base materially through 2030. The central debate among research desks is the terminal market size: estimates diverge sharply on insurance access and discontinuation rates, making the theme as much about execution and supply as about clinical efficacy.
The outlook to 2030
By 2026-2030 the field migrates beyond first-generation GLP-1 monotherapy toward oral small molecules that remove cold-chain and injection friction, and toward amylin and dual or triple agonist combinations targeting higher weight-loss thresholds. Indication expansion into cardiovascular disease, MASH, sleep apnea, and heart failure should extend the franchise well past cosmetic weight management. Whoever resolves the manufacturing and oral-delivery bottleneck first captures the demand that currently exceeds available supply.
What is moving the capital
The forces routing money into this theme right now.
Oral GLP-1 regulatory filings
Lilly's orforglipron met primary endpoints across multiple Phase 3 trials and is on track for global regulatory submission, potentially the first highly scalable oral GLP-1.
Amylin next-gen readouts
Novo's amylin-GLP-1 combination posted strong but below-target data, while Lilly's eloralintide and others race to define the post-GLP-1 standard.
Phase 3 challenger data
Viking's VK2735 dual agonist completed Phase 3 enrollment in both injectable trials, positioning the clearest pure-play readout among smaller developers.
Manufacturing capacity buildout
Supply remains the gating constraint; Lilly and Novo multi-billion fill-finish expansions and CDMO peptide capacity additions determine how fast demand converts to revenue.
リーダー銘柄
Structural large-cap anchors — lower-variance exposure to the theme.
Lilly is a co-leader in the GLP-1 market, anchored by Mounjaro and Zepbound, with a deep pipeline including oral candidates, positioning it as a core holding for investors seeking exposure to this high-growth area. The company's Q1 2026 results demonstrate continued momentum, driven by robust revenue growth and strategic investments in its pipeline.
Why the excitement: Lilly's Q1 2026 earnings call highlighted a 56% revenue increase compared to Q1 2025, fueled by Seman and Monjaro, signaling continued strong demand for its incretin-based therapies.
The honest risk: Despite strong growth, adherence and coverage uncertainty in the anti-obesity drug market, as noted by Goldman Sachs Research, could impact future sales and profitability.
Novo Nordisk is the established GLP-1 market leader, a pure-play on the expanding obesity and diabetes treatment landscape, with a high-margin profile and late-stage pipeline.
Why the excitement: Novo Nordisk's strategic focus on obesity and diabetes drove a 31% increase in obesity care sales in 2025, fueled by Wegovy's expansion into 35 new countries.
The honest risk: Pricing headwinds are expected to impact 2026 results, as noted in the Q4 2025 earnings call.
Amgen offers a diversified approach to capitalizing on the obesity and GLP-1 theme, balancing current revenue streams with a promising, differentiated obesity candidate in development. With a robust portfolio and strategic pipeline progression, Amgen aims to be a key player in the next wave of obesity treatments.
Why the excitement: Amgen's Q1 2026 earnings call highlighted the company's focus on disciplined data generation and execution across important Phase III programs, which management expects will drive attractive long-term growth.
The honest risk: The anti-obesity drug market faces adherence and coverage uncertainty, which could impact the long-term revenue potential of Amgen's obesity candidate.
非対称プレイ
Smaller names with higher upside and deeper potential drawdowns.
Viking Therapeutics is advancing oral and injectable obesity candidates, aiming to capture a piece of the expanding GLP-1 market. With Phase III trials underway and a focus on convenient dosing, Viking is positioning itself as a potential competitor in this space.
Why the excitement: Viking's VANQUISH-1 study was fully enrolled just five months after initiation, exceeding its target enrollment, signaling strong interest in VK2735.
The honest risk: As a clinical-stage company, Viking faces the risk of clinical trial setbacks and the challenge of competing with established players in the GLP-1 market.
Asymmetry: Large upside on trial success or acquisition; deep drawdown on clinical disappointment given pre-revenue status.
Altimmune is a speculative bet on next-generation obesity mechanisms, with its pemvidutide asset targeting both weight loss and liver health. Upcoming Phase III MASH data and Phase II AUD data represent key catalysts.
Why the excitement: Management expects to introduce the 2.4 milligram pemvidutide dose in Phase III, which has achieved additional weight loss in the previous obesity study and could potentially show increased liver efficacy beyond what was observed at the 1.8-milligram dose in Phase II.
The honest risk: As a clinical-stage company, Altimmune faces significant execution risk and uncertainty regarding regulatory approval, despite a strong cash position of $535 million as of April 30, 2026.
Asymmetry: High upside on positive data; sharp drawdown on trial setbacks or cash needs.
Structure Therapeutics is a clinical-stage biotech company developing oral small-molecule GLP-1 receptor agonists, offering a speculative avenue to capitalize on the shift towards convenient, pill-based obesity treatments. The company's amylin program adds another potential growth driver.
Why the excitement: The potential convenience of an oral GLP-1 could unlock significant market share, as patients seek alternatives to injectable medications.
The honest risk: As a clinical-stage company, Structure Therapeutics faces significant clinical trial and regulatory risk, and the possibility of failing to demonstrate sufficient efficacy or safety.
Asymmetry: Upside on oral obesity-drug data; deep drawdown on binary clinical risk.
Inside the theme
The sub-layers and the leaders that anchor each one.
よくある質問
Why is GLP-1 such a large theme?
GLP-1 drugs deliver durable weight loss with expanding cardiovascular and metabolic benefits, creating a market that could reach $130-150B by 2030 — among the largest in pharma history.
The two leaders or the challengers?
Eli Lilly and Novo Nordisk dominate today with lower-volatility exposure; challengers like Viking carry far higher asymmetry tied to clinical data and the convenience shift to oral drugs.
What is the supply-chain angle?
Demand has outrun supply, so contract manufacturers and delivery-device makers benefit regardless of which drug wins — a lower-variance way to ride the trend.
How does the MoonshotScore evaluate this theme?
It weights revenue growth, R&D intensity and cash runway — distinguishing the profitable leaders from pre-revenue challengers with binary trial risk.
What is the main risk?
Challengers face binary clinical outcomes, and even the leaders face pricing pressure, manufacturing constraints and the risk that competition compresses margins over time.
Research sources
- Goldman Sachs Research — The anti-obesity drug market may prove smaller than expected
- Morgan Stanley — GLP-1 Market Expected to More Than Double to $190B by 2035
- Eli Lilly and Company — Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss (ATTAIN-1, NEJM)
- Eli Lilly and Company — Lilly's oral GLP-1 orforglipron successful in third Phase 3 trial, triggering global submissions
- HCPLive — CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial
- BioPharma Dive — Novo's Wegovy successor disappoints in second large trial (CagriSema)
- Amgen — Results from Amgen's Phase 2 Obesity Study of Monthly MariTide (ADA 85th Sessions)
- Viking Therapeutics / PR Newswire — Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Related themes
Biotech & AI Drug DiscoveryAI InfrastructureAI Agents & Agentic Software
投資助言ではなく教育コンテンツ。過去のパフォーマンスは将来の結果を保証しません。